Corbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on Tuesday

Corbus Pharmaceuticals (NASDAQ:CRBP) will likely be announcing its Q4 2025 results before the market opens on Tuesday, March 10th. Analysts expect the company to announce earnings of ($1.78) per share and revenue of $1.1110 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 12:30 PM ET.

Corbus Pharmaceuticals Price Performance

NASDAQ CRBP opened at $8.02 on Friday. The company’s 50 day simple moving average is $8.13 and its 200 day simple moving average is $10.53. Corbus Pharmaceuticals has a 12 month low of $4.64 and a 12 month high of $20.56. The firm has a market capitalization of $140.75 million, a PE ratio of -1.46 and a beta of 2.84.

Insider Buying and Selling at Corbus Pharmaceuticals

In related news, major shareholder Cormorant Asset Management, Lp sold 30,029 shares of Corbus Pharmaceuticals stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $11.46, for a total transaction of $344,132.34. Following the completion of the sale, the insider owned 2,344,971 shares of the company’s stock, valued at approximately $26,873,367.66. This trade represents a 1.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Dominic Smethurst sold 3,285 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $8.09, for a total value of $26,575.65. Following the completion of the transaction, the insider owned 95,887 shares in the company, valued at $775,725.83. This trade represents a 3.31% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 35,729 shares of company stock worth $390,245. 3.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Corbus Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Persistent Asset Partners Ltd acquired a new stake in shares of Corbus Pharmaceuticals during the 4th quarter valued at about $54,000. ADAR1 Capital Management LLC acquired a new position in Corbus Pharmaceuticals in the third quarter worth approximately $129,000. Virtu Financial LLC bought a new position in Corbus Pharmaceuticals during the fourth quarter valued at approximately $88,000. Barclays PLC lifted its stake in Corbus Pharmaceuticals by 280.0% in the fourth quarter. Barclays PLC now owns 14,758 shares of the biopharmaceutical company’s stock valued at $120,000 after acquiring an additional 10,874 shares during the last quarter. Finally, Hudson Bay Capital Management LP acquired a new stake in Corbus Pharmaceuticals in the fourth quarter valued at approximately $139,000. 64.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Royal Bank Of Canada lowered their price target on Corbus Pharmaceuticals from $55.00 to $53.00 and set an “outperform” rating on the stock in a report on Thursday, November 13th. Jefferies Financial Group raised Corbus Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, February 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Sell rating to the company. According to MarketBeat, Corbus Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $44.38.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.